BrainsWay Ltd. (BRSYF) Research

BrainsWay Ltd. is a global medical technology company focused on innovating and providing non-invasive neurostimulation therapies for a broad spectrum of mental health and neurological conditions. Operating across the United States, Europe, Israel, and other international markets, the company's core offering is its Deep Transcranial Magnetic Stimulation (dTMS) platform. This advanced technology is employed in the treatment of numerous disorders, including severe depression, anxious depression, obsessive-compulsive disorder, smoking addiction, bipolar disorders, post-traumatic stress disorder, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's solutions are primarily adopted by psychiatrists, hospitals, and specialized medical centers. The company was established in 2003 and has its headquarters situated in Jerusalem, Israel.

Open BrainsWay Ltd. (BRSYF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.